BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27101571)

  • 1. Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms: A Multicenter Study.
    Moris M; Dawson DW; Jiang J; Lewis J; Nassar A; Takeuchi KK; Lay AR; Zhai Q; Donahue TR; Kelly KA; Crawford HC; Wallace M
    Pancreas; 2016 Oct; 45(9):1353-8. PubMed ID: 27101571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm.
    DiMaio CJ; Weis-Garcia F; Bagiella E; Tang LH; Allen PJ
    Gastrointest Endosc; 2016 Jun; 83(6):1205-9. PubMed ID: 26408423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E
    Yip-Schneider MT; Carr RA; Wu H; Schmidt CM
    J Am Coll Surg; 2017 Oct; 225(4):481-487. PubMed ID: 28739154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal papillary mucinous neoplasms of the pancreas: Cytologic-histologic correlation study and evaluation of the cytologic accuracy in identifying high-grade dysplasia/invasive adenocarcinoma.
    Serinelli S; Khurana KK
    Cytojournal; 2024; 21():6. PubMed ID: 38343764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
    Hoffman DH; Ream JM; Hajdu CH; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Apr; 42(4):1222-1228. PubMed ID: 27900458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
    Das KK; Xiao H; Geng X; Fernandez-Del-Castillo C; Morales-Oyarvide V; Daglilar E; Forcione DG; Bounds BC; Brugge WR; Pitman MB; Mino-Kenudson M; Das KM
    Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain.
    Hara T; Ikebe D; Odaka A; Sudo K; Nakamura K; Yamamoto H; Itami M; Hirata T; Kashimura J; Yamaguchi T
    Ann Surg; 2013 Jun; 257(6):1103-11. PubMed ID: 23364699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
    Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
    Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms.
    Zhuge X; Zhou H; Chen L; Chen H; Chen X; Guo C
    BMC Cancer; 2021 Nov; 21(1):1253. PubMed ID: 34800987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms.
    Bausch D; Mino-Kenudson M; Fernández-Del Castillo C; Warshaw AL; Kelly KA; Thayer SP
    J Gastrointest Surg; 2009 Nov; 13(11):1948-54; discussion 1954. PubMed ID: 19760374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.
    Maker AV; Hu V; Kadkol SS; Hong L; Brugge W; Winter J; Yeo CJ; Hackert T; Büchler M; Lawlor RT; Salvia R; Scarpa A; Bassi C; Green S
    J Am Coll Surg; 2019 May; 228(5):721-729. PubMed ID: 30794864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Indications for Limited Surgery of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Kimura K; Amano R; Ymazoe S; Ohira G; Nishio K; Hirakawa K; Ohira M
    World J Surg; 2017 May; 41(5):1358-1365. PubMed ID: 27882420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid.
    Hata T; Dal Molin M; McGregor-Das A; Song TJ; Wolfgang C; Eshleman JR; Hruban RH; Goggins M
    J Mol Diagn; 2018 Jan; 20(1):46-55. PubMed ID: 29229290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms.
    Penheiter AR; Deelchand DK; Kittelson E; Damgard SE; Murphy SJ; O'Brien DR; Bamlet WR; Passow MR; Smyrk TC; Couch FJ; Vasmatzis G; Port JD; Marjańska M; Carlson SK
    Pancreatology; 2018 Jan; 18(1):46-53. PubMed ID: 29170050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
    J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.